Linezolid: A review of its use in the management of serious gram-positive infections

Drugs

Volumn 61, Issue 4, 2001, Pages 525-551

  Perry, C M ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN; VIRULENCE FACTOR;

AGE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; LIVER FAILURE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS;

BACTERIA (MICROORGANISMS); BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; PEPTOSTREPTOCOCCUS; POSIBACTERIA; STAPHYLOCOCCI; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035063748     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161040-00008     Document Type: Review

References (99)

1. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
2. Linezolid
3. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
4. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin
5. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
6. Expression of virulence factors by grampositive cocci exposed to sub-MIC levels of linezolid
7. Oxazolidinones: A review
8. In vitro activities of U- 100592 and U-100766, novel oxazolidinone antibacterial agents
9. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid
10. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinpristin/dalfopristin and linezolid against staphylococci
11. In vitro activities of oxazolidinone compounds U 100592 and U 100766 against Staphylococcus aureus and Staphylococcus epidermidis
12. Activity of linezolid (LIN) against medically important Gram-positive bacteria from 1997 to 1999
13. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
14. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
15. CP5068, a new carbapenem: In vitro and in vivo activities against MRSA
16. Comparative in vitro activities of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci
17. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy
18. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci
19. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
20. Activity of linezolid on antibiotic-resistant and -susceptible strains of Streptococcus pneumoniae collected from across Canada
21. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci
22. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
23. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates
24. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
25. Current guidelines for the treatment and prevention of nosocomial infections
26. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin
27. Staphylococcus aureus with reduced susceptibility to vancomycin - United States
28. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
29. In-vitro activity of a range of old and new antimicrobials to hetero-vancomycin-intermediate Staphylococcus aureus (hVISA)
30. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom
31. Quinupristin/dalfopristin: A review of its use in the management of serious Gram-positive infections
32. Linezolid is active against Streptococcus pneumoniae resistant to other protein synthesis inhibiting antibiotics
33. Antimicrobial activity of linezolid tested against β-haemolytic streptococci isolated from 100 French hospitals (ColBVH)
34. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
35. Minimum inhibitory concentration determinations for oxazolidinone antimicrobial agents and comparator agents against strains of Rhodococcus equi
36. In vitro activity of linezolid and eperezolid against anaerobic bacteria
37. Linezolid activity compared to those selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft-tissue bite infections in humans
38. In vitro antibiotic synergy against Flavobacterium meningosepticum: Implications for therapeutic options
39. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
40. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766)
41. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model
42. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors
43. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days
44. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid
45. Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days
46. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration
47. Intrapulmonary pharmacokinetics of linezolid
48. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
49. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586
50. 14C]PNU 100766 to healthy human volunteers
51. Effect of age and gender on the single-dose pharmacokinetics of linezolid
52. Pharmacokinetics of linezolid in pediatric patients
53. Single dose pharmacokinetics of linezolid in infants and children
54. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
55. Pharmacokinetics of linezolid in patients with liver disease
56. Linezolid versus vancomycin for the treatment of MRSA infections: Results of a randomized phase III trial
57. Linezolid in the treatment of vancomycin-resistant enterococcus: A dose comparative, multicenter phase III trial
58. Results of treating patients (pts) with significant, resistant, Gram positive, intra-abdominal (IA) infections with linezolid (LNZ)
59. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia
60. Oral linezolid in the treatment of community-acquired pneumonia: A phase III trial
61. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
62. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial
63. Comparison of linezolid and flucloxacillin in the treatment of complicated skin infections: Analysis of European and South African patients in a regional phase III trial
64. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft-tissue infections
65. Re-examining hospital length of stay (LOS) reduction potential in a randomized, multi-center clinical trial of methicillin-resistant Staphylococcal species (MRSS): Linezolid vs. vancomycin
66. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial
67. Linezolid use in patients who are intolerant to or fail vancomycin
68. Compassionate linezolid treatment of severe methicillin-resistant Staphylococcus aureus (MRSA) tracheo-bronchitis following lung transplantation
69. Outcomes of linezolid (LNZ) in patients (pts) with malignancies (CA) and significant gram-positive infections
70. Results of treating bone marrow transplant (BMT) patients (Pts) with linezolid (LNZ) in a compassionate use protocol (CUP) for Gram-positive (GP) infections
71. Efficacy of linezolid in gram-positive infections: Results from two phase II trials
72. Linezolid in the treatment of community-acquired pneumonia: The results of phase II and phase III studies
73. Linezolid versus cephalosporin therapy in the treatment of patients with community-acquired patients: Summary of two randomized trials
74. Linezolid is superior to cephalosporins in treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
75. Linezolid for the treatment of pneumonia in hospitalized children: An open-label, single-arm, multicenter study
76. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid
77. Safety and tolerance of linezolid in phase II trials
78. Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) inhibitor of human monoamine oxidase(MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed
79. Antibiotic resistance: A current perspective
80. Management of patients with vancomycin-resistant enterococci
81. Chemotherapy for Gram-positive nosocomial sepsis
82. Hospital super bugs and the problems they cause
83. Linezolid: A viewpoint
84. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance. Clinical significance and treatment options
85. Emergence of vancomycin resistance in Staphylococcus aureus
86. Practice guidelines for the management of community-acquired pneumonia in adults